Cadrenal Therapeutics, Inc. (CVKD)
Last updated: 2026-10-24 19:44:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Cadrenal Therapeutics, Inc. (CVKD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.99, with a market capitalization of $3.46M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.82 to $14.21. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$3.46M | |
$0.98 | |
$101.25 | |
$0.82 | |
$0.97 | |
2.79K | |
474.28K | |
-- | |
$14.21 | |
$0.82 | |
-- | |
-- |
Cadrenal Therapeutics, Inc. (CVKD) Latest Closing Stock Price
Cadrenal Therapeutics, Inc. (CVKD) last closed at $0.97 as of 2026-10-23 23:31:00, unchanged from the previous close of $0.97.
During the latest regular trading session, CVKD traded between $0.82 and $101.25, with a volume of 2.79K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Cadrenal Therapeutics, Inc. (CVKD) 7-Day Stock Price Change
Over the past seven days, Cadrenal Therapeutics, Inc. (CVKD) moved from $0.97 to $0.99, representing a gain of 1.55% ($0.02).
The stock traded between $0.93 and $1.12 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 81.10 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
CVKD 52-Week Price Position
Position in Range: 1.3%
CVKD is currently trading at $0.99, placing it 1.3% of the way from its 52-week low of $0.82 to its 52-week high of $14.21. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Cadrenal Therapeutics, Inc. (CVKD)?
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
Cadrenal Therapeutics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Cadrenal Therapeutics, Inc. (CVKD) Stock on MEXC
Eligible investors can buy real shares of Cadrenal Therapeutics, Inc. (CVKD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Cadrenal Therapeutics, Inc. (CVKD) stock price today?
2.Is CVKD stock going up or down today?
3.What is CVKD pre-market price?
4.What is CVKD after-hours price?
5.Is CVKD stock trading now?
6.Where does CVKD sit relative to its 52-week high and low?
7.What sector is Cadrenal Therapeutics, Inc. in?
8.What is Cadrenal Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is CVKD valued in terms of P/E ratio and EPS?
10.Does Cadrenal Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
CVKD Stock Calculator
Estimate the value between CVKD shares and USD.
CVKD Shares to USD
1.00 CVKD shares = 0.985 USD
Calculations are estimates based on the latest available price and are for reference only.


